Genflow Biosciences (GENF) Share Price, News & Analysis

Company Overview

Genflow Biosciences plc, together with its subsidiaries, operates as a biotechnology company that focuses on developing biological interventions aimed at tackling the effects of ageing, slowing, and halting the ageing process, and reducing the incidence of age-related diseases with increase in health span in the United Kingdom and Belgium. Its lead compound is GF-1002, a suspension of an adeno-associated viral vector-based gene therapy for intravenous infusion. The company is also developing GF-3001, a topical delivery of SIRT6 to the skin; and GF-4001, a non-human pipeline anti-aging for veterinary use. Genflow Biosciences plc was incorporated in 2021 and is headquartered in London, the United Kingdom.

Key Stats

• Today's Range: 1.70 to 1.80
• 50-Day Range: 1.67 to 2.29
• 52-Week Range: 1.32 to 3.41
• Volume: 550,706 shs
• Average Volume: 993,169 shs
• Market Capitalization: £6.12 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

GENF Stock Analysis - Frequently Asked Questions

How have GENF shares performed this year?

Genflow Biosciences' stock was trading at GBX 1.43 at the beginning of the year. Since then, GENF shares have increased by 22.8% and is now trading at GBX 1.75.
View the best growth stocks for 2024 here.

How do I buy shares of Genflow Biosciences?

Shares of GENF stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
Compare Top Brokerages Here.

What other stocks do shareholders of Genflow Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Genflow Biosciences investors own include Aehr Test Systems (AEHR), Advanced Micro Devices (AMD), ARM (ARM), Medical Properties Trust (MPW), NIO (NIO), NVIDIA (NVDA) and PayPal (PYPL).

Industry, Sector and Symbol

• Stock Exchange: LON
• Sector: Medical
• Industry: Biotechnology
• Sub-Industry: N/A
• Current Symbol: LON:GENF
• CUSIP: N/A
• CIK: N/A
• Web: genflowbio.com
• Phone: 44 32 4774 95881
• Fax: N/A
• Employees: 5
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): GBX (0.01)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: £-1,530,000.00
• Net Margins: -256.07%
• Pretax Margin: N/A
• Return on Equity: -118.88%
• Return on Assets: -58.66%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 2.73
• Quick Ratio: 20.20

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 349,710,000
• Free Float: N/A
• Market Cap: £6.14 million
• Optionable: Not Optionable
• Beta: 2.37